
Pharmacally
Breast Cancer
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Breast Cancer
Health TidingsIksuda Reports 50% ORR With IKS014 After T-DXd in HER2+ Breast CancerIksuda Therapeutics reported a 50% objective response rate with its HER2-directed ADC IKS014 in a small group of heavily pretreated HER2-positive breast cancer patients previously treated with trastuzumab…Fact-Checked
Clinical TrialsBioNTech and DualityBio Report Modest PFS Gain but Higher ILD in Breast Cancer TrialBioNTech and DualityBio’s phase 3 DYNASTY-Breast02 trial met its primary PFS endpoint for trastuzumab pamirtecan in HR-positive/HER2-low metastatic breast cancer.Fact-Checked
Mergers & AcquisitionsPrelude and Lilly Partner to Test PRT13722 Combinations in HR+/HER2− Breast CancerPrelude Therapeutics and Lilly will evaluate PRT13722 with abemaciclib and imlunestrant in a Phase 1 trial for HR+/HER2− breast cancer…Fact-Checked
New Drug ApprovalFDA Approves TUKYSA as First-Line Maintenance in Breast CancerPfizer’s TUKYSA (tucatinib) gains FDA approval for first-line maintenance in HER2-positive metastatic breast cancer after induction therapy, following an 8.6-month improvement in median progression-free survival in HER2CLIMB-05.Fact-Checked
New Drug ApprovalEU Approves Datroway for Metastatic Triple-Negative Breast CancerThe European Commission has approved Datroway (datopotamab deruxtecan) for the first-line treatment of adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor…Fact-Checked
New Drug ApprovalAstraZeneca’s Etcamah Wins EU Approval for ESR1-Mutated HR-Positive Advanced Breast CancerThe European Commission has approved AstraZeneca’s Etcamah (camizestrant) with CDK4/6 inhibitors for adults with ESR1-mutated ER-positive, HER2-negative advanced breast cancer.Fact-Checked
New Drug ApprovalFDA Approves REVTORPYK for PIK3CA Wild-Type HR+/HER2- Advanced Breast CancerThe FDA has approved REVTORPYK (gedatolisib) with fulvestrant, with or without palbociclib, for adults with PIK3CA wild-type HR-positive/HER2-negative locally advanced or metastatic breast cancer after endocrine therapy.Fact-Checked
Mergers & AcquisitionsAstex Signs Breast Cancer Drug Discovery Deal with GenentechAstex Pharmaceuticals has signed an exclusive global research collaboration and licensing agreement with Genentech to advance a novel small-molecule breast cancer program targeting a key cell-cycle regulator.Fact-Checked
Clinical TrialsCelcuity’s Gedatolisib Delivers Strong Phase 3 Win in Advanced Breast CancerCelcuity Celcuity’s Phase 3 VIKTORIA-1 trial shows gedatolisib-based regimens doubled progression-free survival versus alpelisib in HR+/HER2-, PIK3CA-mutated advanced breast cancer…Fact-Checked
Health TidingsRoche’s Giredestrant Wins FDA Priority Review for Early Breast CancerRoche has advanced its breast cancer pipeline with FDA acceptance of a Priority Review NDA for giredestrant in stage I–III ER-positive/HER2-negative disease.Fact-Checked
Health TidingsFDA Extends Review of Camizestrant in ESR1‑Mutant Breast CancerThe FDA has delayed its decision on AstraZeneca’s camizestrant combination for ESR1‑mutant HR‑positive, HER2‑negative advanced breast cancer, extending the PDUFA timeline after requesting further analyses from the Phase…Fact-Checked
Health TidingsCHMP Issues Positive Opinion for Camizestrant in ESR1‑Mutant Breast CancerThe European Medicines Agency’s CHMP has recommended camizestrant in combination with a CDK4/6 inhibitor for patients with ER+/HER2‑ advanced breast cancer who develop ESR1 mutations during first‑line endocrine…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.